NEW YORK (GenomeWeb News) – Shares of Helicos BioSciences were downgraded today to "market perform" from "outperform" by Leerink Swann analyst Isaac Ro.

The analyst said that the stock was lowered in consideration of Helicos' "near-term funding challenges."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.